Please login to the form below

Not currently logged in
Email:
Password:

Boehringer, EFSD offer €2.5m in diabetes research grants

Application accepted up until April 1, 2013

German pharma company Boehringer Ingelheim has teamed up with the European Foundation for the Study of Diabetes (EFSD) to offer more than €2.5m in funding for research projects over the next three years.

The fund is accepting applications until April 1 and is offering grants of up to €100,000 for basic research projects lasting up to two years, and a ceiling of €400,000 over three years for clinical research projects.

The announcement renews a funding and research collaboration between Boehringer and the EFSD which initially got underway in 2011.

The programme will focus on two areas of diabetes research, namely the regulations of secretion and/or function of non-insulin peptides from the endocrine pancreas - which will be open to basic research applicants - and mechanisms relating renal dysfunction to cardiovascular disease in type 2 diabetes which will cover clinical and translational research projects.

"Diabetes affects more than 371 million people worldwide and diabetes remains undiagnosed in up to 50 per cent of cases," said Professor Klaus Dugi, Boehringer's corporate senior vice president for medicine.

"We are delighted to partner with the EFSD on this initiative and hope the grant encourages and supports new research in the field of diabetes," he added.

Applications are open to single non-profit institutions or groups of institutions in Europe and associated countries, and the applications will be subject to a scientific review by a specialised and independent committee.

EFSD also has funds available for other pharma company-sponsored projects, including programmes run alongside Novo Nordisk, Johnson & Johnson subsidiary Janssen, Eli Lilly and Merck Sharp & Dohme (MSD), with deadlines for applications due from February 1 onwards.

18th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. We are an award-winning agency with over 30...

Latest intelligence

Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...
So how do you really engage with patients?
The most valuable insights from patient engagement are the most unexpected ones. Simple things, which may seem unimportant to you, may be the key to making patients’ lives easier and...
data
Avoiding data pitfalls in clinical research
Genomics sequencing and sensors will present new challenges...

Infographics